The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
The U.S. Food and Drug Administration (FDA) has granted priority review for Roche’s Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
The FDA is expected to make a decision on approval by Jan 28, 2018, it said in a statement.
A clinical trial for the combination therapy resulted in a modest benefit for patients, but Roche has expressed confidence that Perjeta will drive sales as it tries to offset the hit from cut-price competition to top-selling biological cancer medicines.
Related posts:
US FDA approves Genmab-AbbVie’s Blood Cancer therapy for adult patients
Takeda’s Zika vaccine gets U.S. FDA’s ‘fast track’ status
Elon Musk’s Neuralink gets FDA approval for first human brain implant trial
Navy Officers Wives remind Women to watch for Early Signs of Breast Cancer
Eli Lilly wins U.S. approval for breast cancer drug
Late night dinner increases risk of breast, prostrate cancer
Actress Kelly Preston dies of breast cancer at 57
Sokoto Govt promises partnership with Health Professionals to combat scourge of breast cancer
